JP2005516907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516907A5 JP2005516907A5 JP2003547457A JP2003547457A JP2005516907A5 JP 2005516907 A5 JP2005516907 A5 JP 2005516907A5 JP 2003547457 A JP2003547457 A JP 2003547457A JP 2003547457 A JP2003547457 A JP 2003547457A JP 2005516907 A5 JP2005516907 A5 JP 2005516907A5
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- primate
- antibody
- molecule
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100037850 Interferon gamma Human genes 0.000 claims 10
- 108010074328 Interferon-gamma Proteins 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 241000288906 Primates Species 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01870266 | 2001-11-30 | ||
| US34149901P | 2001-12-17 | 2001-12-17 | |
| EP02447043 | 2002-03-25 | ||
| PCT/EP2002/013358 WO2003046008A1 (en) | 2001-11-30 | 2002-11-27 | Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516907A JP2005516907A (ja) | 2005-06-09 |
| JP2005516907A5 true JP2005516907A5 (enExample) | 2006-01-05 |
Family
ID=56290362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547457A Pending JP2005516907A (ja) | 2001-11-30 | 2002-11-27 | 霊長類ｉｆｎ−ガンマ結合分子の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030211103A1 (enExample) |
| EP (1) | EP1463761A1 (enExample) |
| JP (1) | JP2005516907A (enExample) |
| AU (1) | AU2002365514A1 (enExample) |
| CA (1) | CA2467647A1 (enExample) |
| WO (1) | WO2003046008A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4673068B2 (ja) * | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| EP2221619A1 (en) | 2006-09-12 | 2010-08-25 | F. Hoffmann-La Roche AG | Anti-drug antibody assay |
| AU2007327995B2 (en) * | 2006-12-06 | 2013-10-10 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| EP2068924A4 (en) * | 2007-05-03 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS |
| US20100261172A1 (en) * | 2007-05-03 | 2010-10-14 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| AU2019210034B2 (en) | 2018-01-19 | 2025-03-27 | Generation Bio Co. | Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| CN114747535B (zh) * | 2022-03-29 | 2024-03-22 | 华南理工大学 | 一种急性脓毒症非人灵长类动物模型及其构建方法 |
| WO2025224314A1 (en) * | 2024-04-26 | 2025-10-30 | Swedish Orphan Biovitrum Ag | Use of emapalumab for treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1015480A2 (en) * | 1997-08-18 | 2000-07-05 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
-
2002
- 2002-11-27 WO PCT/EP2002/013358 patent/WO2003046008A1/en not_active Ceased
- 2002-11-27 AU AU2002365514A patent/AU2002365514A1/en not_active Abandoned
- 2002-11-27 CA CA002467647A patent/CA2467647A1/en not_active Abandoned
- 2002-11-27 JP JP2003547457A patent/JP2005516907A/ja active Pending
- 2002-11-27 EP EP02803800A patent/EP1463761A1/en not_active Withdrawn
-
2003
- 2003-04-28 US US10/424,598 patent/US20030211103A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503588A5 (enExample) | ||
| JP2003503454A5 (enExample) | ||
| JP2006512316A5 (enExample) | ||
| JP2005516907A5 (enExample) | ||
| JP2007510639A5 (enExample) | ||
| JP2007511593A5 (enExample) | ||
| WO2002060900A3 (en) | Antagonists of mcp-1 function and methods of use thereof | |
| ATE384035T1 (de) | Ether-verbindungen, zusammensetzungen und ihre verwendung | |
| JP2006526031A5 (enExample) | ||
| JP2005526058A5 (enExample) | ||
| JP2002179603A5 (enExample) | ||
| ATE524184T1 (de) | 2,4-pyrimidindiamin-verbindungen und ihre verwendungszwecke | |
| NO20034996D0 (no) | Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser | |
| JP2007514005A5 (enExample) | ||
| WO2005113534A3 (en) | Cxcr1 and cxcr2 chemokine antagonists | |
| JP2008513510A5 (enExample) | ||
| JP2006506499A5 (enExample) | ||
| WO2006078925A3 (en) | A tetracycline metal complex in a solid dosage form | |
| JP2005527457A5 (enExample) | ||
| WO2002072086A3 (en) | Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases | |
| JP2008515980A5 (enExample) | ||
| FR2865403B1 (fr) | Composition pour le traitement d'une pathologie associee a la msrv/herv-w | |
| WO2007002764A3 (en) | Di-substituted oxadiazoles as cxc-chemokine receptor ligands | |
| WO2006050861A3 (en) | Statine derivatives for the treatment of alzheimer's disease | |
| WO2007002722A3 (en) | Synthesis of anastrozole and purification of one of its intermediate |